Effect of Ellagic Ácid on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Metabolic syndrome (MS) is a group of important cardiovascular risk factors: abdominal
obesity, dyslipidemia, hyperglycemia, and high blood pressure. Treatment requires the
introduction of pharmacological management that includes different medications for each
component. Ellagic acid (EA) is a polyphenol that has shown health benefits in multiple
experimental studies. AE is consumed by patients without a prescription; considering there
aren't studies that demonstrate it's effectiveness on MS, it is important to evaluate the
possible effects of AE on this pathology. METHODOLOGY: Current study is a double-blind,
placebo-controlled clinical trial. The aim of this study is evaluating the effect of AE on
the components of metabolic syndrome, insulin sensitivity, and insulin secretion.
Phase:
Phase 2
Details
Lead Sponsor:
University of Guadalajara
Collaborator:
National Council of Science and Technology, Mexico